Prohibitionist Groups File Lawsuit to Overturn Federal Cannabis Rescheduling

A coalition of prohibitionist organizations, including Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association, has filed a lawsuit aiming to reverse the Department of Justice's recent move to reschedule cannabis. The groups are represented by a firm where former Attorney General William Barr is a partner, signaling significant political and legal firepower behind the challenge. This legal action comes on the heels of a historic federal decision to reclassify marijuana, which advocates say could pave the way for expanded medical use and research

Federal cannabis policy continues to generate heated debate in Washington. Senate Banking Committee Chairman Tim Scott (R-SC) acknowledged the difficulties faced by the marijuana industry in accessing financial services, calling it a “quandary” and expressing optimism that a solution will be found. Meanwhile, Senator Rand Paul (R-KY) is pushing back against efforts to ban hemp, warning, “Washington wants to ban hemp overnight and wipe out a $28 billion American industry.” These comments highlight the ongoing struggle to balance regulation, public health, and economic interests as cannabis laws evolve

At the state level, momentum for cannabis reform is building. The Pennsylvania Senate Law & Justice Committee has advanced a bill to establish a Cannabis Control Board, which would oversee medical marijuana, hemp, and potentially recreational cannabis if legalized. In North Carolina, lawmakers have introduced a bill that would place two marijuana-related questions on the November ballot, giving voters the opportunity to weigh in on both medical and personal use legalization. Additionally, a coalition of advocacy groups is urging Virginia Governor Abigail Spanberger not to veto legislation that would legalize recreational cannabis sales, despite her proposed amendments being rejected by lawmakers

Legal and regulatory developments are also unfolding in several other states. The Massachusetts Supreme Judicial Court recently held a hearing on whether to allow an initiative that would roll back cannabis legalization to appear on the November ballot. Nevada and Colorado regulators are updating their cannabis rules and guidance in response to federal rescheduling. In the business sector, major operators like Cresco Labs, Green Thumb Industries, Verano Holdings, and Curaleaf are facing class action lawsuits over alleged false medical claims, while Curaleaf reported quarterly net revenue of $324.2 million, and Rhode Island saw $29.5 million in legal cannabis sales in Q1 2026

Scientific and health research continues to inform policy discussions. Recent studies have found no association between prenatal cannabis exposure and disrupted cognitive or language development in young children, and have identified CBD as a promising candidate for treating infectious bronchitis in chickens. These findings contribute to a growing body of evidence that policymakers and industry stakeholders are closely monitoring as cannabis regulations evolve

From the OG Lab perspective, this surge in legal, political, and scientific activity underscores a pivotal moment for the cannabis industry. The lawsuit to reverse rescheduling could set a major precedent, while state-level reforms and ongoing scientific studies will shape the regulatory and market environment for years to come. As the landscape shifts, stakeholders should keep a close eye on court outcomes and legislative actions that could either accelerate or hinder cannabis normalization across the United States